Tumor necrosis factor-alpha (TNF-α) monoclonal antibody, infliximab, has revolutionized IBD treatment, demonstrating its efficacy to induce clinical remission and mucosal healing (MH) in patients who were refractory to conventional therapies [2,3]. This evidence concerns the gene TNF and inflammatory bowel disease.